Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WT1 mRNA-electroporated Dendritic Cell Vaccine for High-Risk MDS and AML
NCT03083054Phase 2Unknown
- Sponsor
- Universidade Estadual de Campinas
- Start
- Aug 2016
- Primary completion
- Jul 2020
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of WT1 mRNA-loaded autologous monocyte-derived dendritic cells in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), sponsored by Universidade Estadual de Campinas. Primary endpoint: Disease free survival at 12 months. Status: unknown.
02
Drugs
WT1 mRNA-loaded autologous monocyte-derived dendritic cells
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03083054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03083054.